Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis

Journal of Infectious Diseases

Volumn 179, Issue 3, 1999, Pages 743-746

  Sang, David K ^a,b   Ouma, John H ^a,b   John, Chandy C ^a,b   Whalen, Christopher C ^a,b   King, Christopher L ^a,b   Mahmoud, Adel A F ^a,b   Heinzel, Frederick P ^a,b  

^a MINISTRY OF HEALTH   (Kenya)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FANSIDAR; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; STIBOGLUCONATE SODIUM;

ANTIBIOTIC THERAPY; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CYTOKINE RELEASE; HUMAN; IMMUNOMODULATION; KENYA; PRIORITY JOURNAL; SERUM; VISCERAL LEISHMANIASIS;

ANIMALS; HUMANS; KENYA; LEISHMANIASIS, VISCERAL; MICE; NORTH AMERICA; PAPUA NEW GUINEA; RECEPTORS, INTERLEUKIN-2; RECEPTORS, INTERLEUKIN-4; RECOMBINANT PROTEINS; REFERENCE VALUES;

EID: 0033386439     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314635     Document Type: Article

References (15)

1. 1. Magill AJ. Epidemiology of the leishmaniases. Dermatol Clin 1995;13: 505-23.
2. 2. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 1994;152:5949-56.
3. 3. Ghalib HW, Piuvezam MR, Skeiky Y, et al. Interleukin-10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993;92:324-9.
4. 4. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995;13:151-77.
5. 5. Cillari E, Vitale G, Arcoleo F, et al. In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine 1995;7:740-5.
6. 6. Zwingenberger K, Harms G, Pedros C, Omena S, Sandkamp B, Neifer S. Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin-4 over interferon-γ production. Clin Immunol Immunopathol 1990;57:242-9.
7. 7. Fernandez-Botran R, Wynn TA, Hieny S, Caspar P, Chilton PM, Sher A. Linked in vivo expression of sofuble interleukin-4 receptor and interleukin-4 in murine schistosomiasis. Eur J Immunol 1995;25:649-56.
8. 8. Fernandez-Botran R, Chilton PM, Ma Y. Soluble cytokine receptors: their roles in immunoregulation, disease and therapy. Adv Immunol 1996;63: 269-336.
9. 9. Barral-Netto M, Barral A, Santos SB, et al. Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis. J Immunol 1991;147:281-4.
10. 10. Badaro R, Benson D, Eulalio MC, et al. rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis 1996;173: 758-61.
11. 11. Konig B, Neuber K, Konig W. Responsiveness of peripheral blood mononuclear cells from normal and atopic donors to microbial superantigens. Int Arch Allergy Immunol 1995;106:124-33.
12. 12. Blum H, Wolf M, Enssle K, Rollinghoff M, Gessner A. Two distinct stimulus-dependent pathways lead to production of soluble murine interleukin-4 receptor. J Immunol 1996;157:1846-53.
13. + T cell responses capable of exacerbating leishmaniasis in normally resistant C57BL/6 mice. J Immunol 1995;155:730-9.
14. 14. Gessner A, Schroppel K, Will A, Enssle KH, Lauffer L, Rollinghoff M. Recombinant soluble interleukin-4 (IL-4) receptor acts as an antagonist of IL-4 in murine cutaneous Leishmaniasis. Infect Immun 1994;62:4112-7.
15. 15. Schulte T, Kurrle R, Rollinghoff M, Gessner A. Molecular characterization and functional analysis of murine interleukin-4 receptor allotypes. J Exp Med 1997;186:1419-29.